Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia

Inclusion Criteria: 1. Male or female subjects aged 18 to 85 years 2. The subjects are diagnosed with community-acquired pneumonia (CAP) at the time of hospital admission and must meet all of the following criteria: Chest X-ray showing new onset or persistent pulmonary infiltrate At least two of the following abnormal clinical or laboratory findings: (a) Cough, (b) Sputum production, (c) Fever (≥37.8℃) or hypothermia (\<35℃), (d) Auscultatory findings of rales or bronchial breath sounds, (e) White blood cell count greater than 10×10⁹/L or less than 4×10⁹/L 3. Subjects requiring hospitalization and intravenous antibiotic therapy 4. Subjects who have received standard antibiotic therapy for less than 24 hours after hospital admission 5. Subjects who are able to take the investigational product orally 6. Subjects who are able to understand and comply with all study procedures and provide written informed consent Exclusion Criteria: 1. Subjects who have received systemic antibiotic treatment within 72 hours prior to screening; routine antibiotics administered after hospital admission are not included in this restriction 2. Subjects who have used oral traditional Chinese medicine (TCM) or traditional Chinese medicine preparations that may affect efficacy assessment within 7 days prior to hospital admission 3. Subjects who have been hospitalized within 15 days prior to current admission 4. Subjects with aspiration pneumonia 5. Subjects requiring admission to the intensive care unit (ICU) 6. Subjects requiring hemodialysis 7. Subjects with any malignancy, except those who have completed curative treatment with no signs of recurrence for more than five years and require no further anticancer therapy (based on medical history) 8. Subjects with human immunodeficiency virus (HIV) infection 9. Subjects requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), steroids, or other immunosuppressants 10. Subjects requiring antiviral agents for COVID-19 infection or influenza 11. Subjects must be on a stable dose of Omeprazole or Warfarin 12. Subjects with alcohol or substance abuse, or other major organic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, tuberculosis (TB), or significant heart, kidney, or other major organ dysfunction or failure (based on medical history) 13. Female subjects who are pregnant, breastfeeding, or of childbearing potential, or those intending to become pregnant between the signing of the Informed Consent Form (ICF) and the final observation/study time point, or who are unwilling to use an appropriate method of contraception. Acceptable highly effective methods of contraception include: 1. Surgical sterilization (male or female), contraceptive implants, or intrauterine devices (IUDs). 2. Injectable contraceptives, oral contraceptives, contraceptive patches, or vaginal rings, used in combination with one barrier method.\* 3. Combination of two barrier methods.\* \*Effective barrier methods include diaphragms, male or female condoms, contraceptive sponges, or spermicides (creams or gels containing spermicidal chemicals). 14. Subjects deemed unsuitable for study participation by the investigator